Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234
关于短期局部应用重组人神经生长因子(rhNGF)治疗青光眼神经增强的1b期随机对照研究的更正:安全性、耐受性和疗效指标结果。《美国眼科杂志》2022;234:223-234
期刊:American Journal of Ophthalmology
影响因子:4.2
doi:10.1016/j.ajo.2022.07.018
Beykin, Gala; Stell, Laurel; Halim, Muhammad Sohail; Nuñez, Mariana; Popova, Lilia; Nguyen, Bac T; Groth, Sylvia L; Dennis, Amy; Li, Zhongqiu; Atkins, Melissa; Khavari, Tom; Wang, Sophia Y; Chang, Robert; Fisher, Ann C; Sepah, Yasir J; Goldberg, Jeffrey L